• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 16, 2024
Distillery Therapeutics

Increasing N-acetyltaurine levels for obesity

Read More
BioCentury | Jul 18, 2024
Finance

Venture Report: Five biotechs raise nearly $800M in two-day flurry 

Plus: New capital for CytoReason, Truvian and Renalys
Read More
BioCentury | Aug 10, 2023
Product Development

Obesity mechanisms in the clinic: which overlap, and which branch out

Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss
Read More
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

BioCentury’s roundup of preclinical news
Read More
BioCentury | Oct 5, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

Read More
BioCentury | Oct 3, 2017
Distillery Therapeutics

Endocrine / Metabolic

Read More
BioCentury | Oct 2, 2017
Preclinical News

NGM targeting GFRAL for both obesity and cachexia

Read More
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Why pharmas think GFRAL could be the next obesity target
Read More
BioCentury | Aug 28, 2017
Preclinical News

Teams identify GFRAL as target for obesity

Read More
Items per page:
1 - 9 of 9